



"Establishing an *in vitro* fiber toxicity test strategy to support risk assessment and facilitate grouping"

**4<sup>th</sup> Joint Symposium on Nanotechnology**

Rico Ledwith

# Carbon Nanotubes (CNTs)

- **CNTs** are tubular structures made of layer(s) of graphene
- Single-walled CNTs (**SWCNTs**): Single graphene sheet rolled up
- Multi-walled CNTs (**MWCNTs**): Consisting of multiple sheets forming concentric cylinders


- **Properties** that make **MWCNTs** useful for industrial applications

- Tensile strength
- Electrical and thermal conductivity

- **Usages**

- Antistatic and electro-paintable thermoplastics
- Anti-fouling coatings
- Batteries (Li-ion)
- Structural composites (*e.g.*, for windmill blades and high performance sporting goods)
- Possibly printed electronics (conductive inks) and conductive coatings for displays and touch screens

## CNT classifications:




Negri, V et al., *Top Curr Chem (Z)* 378, 15 (2020). DOI: 10.1007/s41061-019-0278-8

- Fiber - shaped nanomaterials are also referred to as High-Aspect Ratio Nanomaterials (**HARNs**)

# Concerns

- ❖ **MWCNTs** may elicit similar toxicity to highly pathogenic **asbestos** fibers due to their morphological similarity
- ❖ Inhalation is the main route of exposure

**Amphibole class:** Amosite (needle-like fibers)



SEM image of amosite fibers detached from an asbestos cement roof

Campopiano et al. *Annals of Occupational Hygiene*, Vol 53 (6) 2009, DOI: 10.1093/annhyg/mep036

- Asbestos is banned in the EU
  - Amphiboles - 1991
  - Serpentine - 2005

## Asbestos associated pathologies:

- **Fibrosis:** Long term inflammation and scarring of the lungs
- **Lung Cancer:** Malignant neoplasm of the lung arising from the epithelium
- **Mesothelioma:** Cancer arising from the transformation of **mesothelial cells** lining the thoracic (pleura) or the abdominal (peritoneum) cavities
  - Aggressive, non-curable cancer
  - Uniquely associated with asbestos exposure
  - **Long latency period!**

## What physiochemical features render a fiber pathogenic?

→ **Fiber pathogenicity paradigm**

# What properties of fibers imbue them with pathogenicity?

❖ **Fiber Pathogenicity Paradigm (FPP):** Structure toxicity model that predicts whether a fiber is, or is not pathogenic

## World Health Organization (WHO) Criteria:

### 1. Inhalable diameter ( $D_{ae} < 3 \mu\text{m}$ ):

- Deposition in the distal lung beyond ciliated airways


### 2. Length ( $> 5 \mu\text{m}$ ):

- Escape clearance mechanisms, e.g.:
  - **Alveolar Macrophages ( $> 15 \mu\text{m}$ ):** Long fibers can not be engulfed  
→ **Frustrated Phagocytosis!**


### 3. Aspect Ratio: $> 3:1$

### 4. Biopersistence:

- Leads to prolonged retention in lung and accumulation over time
- Pathogenic fibers are typically not dissolvable



Schinwald, A. et al. *Part Fibre Toxicol* 9, 34 (2012). doi.org/10.1186/1743-8977-9-34



Frustrated phagocytosis observed for amosite asbestos by NR8383 rat alveolar macrophages

Donaldson et al., *Nanomedicine*, doi.org/10.2217/nmm.10.139

Very long fibers cannot be fully engulfed by macrophages, causing frustrated phagocytosis → **Inflammation** → **Cancer development**



# Challenges of nanofibers

❖ Nanofibers pose a challenge to the WHO fiber criteria


**Classical FPP:** Respirable, long and biopersistent fibers are carcinogenic

**Rigidity hypothesis:** Only long, rigid nanofibers act as fibers while flexible (i.e. thin) nanofibers curl up

- *In vivo* studies on MWCNTs indicated a diameter threshold for carcinogenicity > 30 nm


❖ Further implications of secondary structures

- Some types of non-rigid MWCNTs can form highly ordered **secondary structures**
- **Aligned bundles** comply with the WHO criteria
- **Fiber paradigm might apply**




Macrophages perform the „Al-dente“-test  
(Images by Asmus Meyer-Plath, BAuA)

Primary structure:



Singlet tube

Possible secondary structure:



Aligned bundle

Simonow, B.K. et al. *J Nanopart Res* 20, 154 (2018). DOI: 10.1007/s11051-018-4262-y

# Regulatory activities on MWCNT by Germany (BfR)

## Rigid MWC(N)T (diameter > 30 nm)

- Harmonised classification (2018-21)

Classification and labelling should be harmonised throughout the EU **to ensure a high level of protection of human health.**

→ Fiber-like pathomechanism



**Carc. 1B**, “*Presumed human carcinogen*”

**STOT-RE 1**, Specific Target Organ Toxicity – Repeated Exposure, lung by inhalation  
(„*Substance produces significant toxicity*“)



**Enables authorities to conduct further regulatory risk management.**

E.g. substitution of CMR substances

## Tangled MWCNT (diameter < 30 nm)

- Substance Evaluation (SEv, 2019)

For clarifying whether their use poses a risk to human health.



During the SEv **additional information can be requested** from the registrants of the substance **to verify the suspected concern**, if necessary.







Registrants applied **grouping and read across approaches** to avoid additional testing.

# What is Grouping?

- ❖ Testing of each nanomaterial for their potential adverse effects is virtually impossible
- ❖ Grouping is the most commonly used alternative approach for filling data
- Structural similarity allows to predict properties of substances without having to test them all for each endpoint ('read-across')

## Endpoint-specific grouping

- For toxicity evaluation (endpoint-specific category building)

Endpoint	
Acute toxicity	
Sub-chronic toxicity	
Mutagenicity	
Skin sensitization	
....	

- A high aspect ratio and potential biopersistence are key factors for the toxicity and pathogenicity of fibres, these properties can be used for grouping
- Frameworks have been developed in the form of integrated approach to testing and assessment (**IATA**) to support this grouping

# GRACIOUS grouping framework






Figure 1: Basic structure of the GRACIOUS Framework.



**IATA** consisting of multiple **decision nodes** (blue boxes) are used to collate the required information to test a grouping hypothesis



# Testing strategies and uncertainties



GRACIOUS Framework Guidance Document

## Pre-defined HARN hypothesis:

“Respirable, biopersistent, rigid HARN: Following inhalation exposure, long-term pulmonary retention of HARNs can occur, resulting in lung toxicity”

## Uncertainty associated with HARN IATA

- How to measure rigidity?
  - No standardized or validated method available
- How to measure inflammation that is fiber specific?
- How to measure frustrated phagocytosis?
  - Biomarker detection by means of omics

# EU HARMLESS project




Grant Agreement : 953183

Advanced **H**igh **A**spect **R**atio and **M**ulticomponent Materials: Towards comprehensive intelLigent tESting and **S**afe by design **S**trategies

Coordination: Helmholtz Zentrum München (HMGU)  
Partner: 20 (research, governmental, SME, industry)  
from 12 countries  
Budget/ Funding: 8 Mill Euro, (EU NMBP-16)  
Duration: 4 years (started 01.01.2021)


- WP1: Data Collection and Data Management
- WP2: Safety Assessment Strategies
- WP3: New Approach Methodologies
- WP4: Safe Innovation Approach
- WP5: DSS Tool Development
- WP6: SbD Case Studies
- WP7: Stakeholder Engagement
- WP8: Coordination and Management



# Materials

- **MWCNT**

- Various morphologies (Thin, Thick, Short)
- NM-400 / NM-401
- **Mitsui – 7**
  - Benchmark material for a carcinogenic fiber



Di Ianni, *Part Fibre Toxicol.*, 2021, doi: 10.1186/s12989-021-00413-2

Project partners provide:

- Physiochemical characterization data
- *In vivo* data

# Cell models

The air-blood barrier:

- Alveolar Epithelium acts as a **diffusional barrier**
- Macrophages represent an **immunological barrier**


❖ Step 1: Monocultures (*my task*)

## A549: Human, epithelial adenocarcinoma cells

- **Advantages:** Widely used as a TII pulmonary epithelial cell model
- **Disadvantages:** Do not form **functional tight junctions** (no barrier) / Cancer cells

## hAELVi: Human alveolar epithelial lentivirus immortalized

- **Advantages:** Tight junction formation / Physiologically closer to alveolar cells  
High trans-epithelial electrical resistance ( $> 1000 \Omega \cdot \text{cm}^2$ )



## THP-1: Human acute monocytic leukaemia cell line

- **Advantages:** Can be differentiated to macrophages –like cells with phorbol 12-myristate-13-acetate (**PMA**)  $\rightarrow$  dTHP-1
- **Disadvantages:** Cancer cells

## Primary monocytic cells


- **Advantages:** Can be differentiated to macrophages like cells
- **Disadvantages:** Slow proliferation / finite lifespan



# Proteomics

○ Proteomics is applied to mechanistically unravel the mode of action (**MoA**) of HARNs


**Mechanistic Toxicology Data**  
(Omic, Biomarkers)



**Outlook: Validation**

- Phagocytosis inhibitors: Cytochalasin D
- Western Blots
- Confocal microscope imaging, e.g. of cytoskeletal proteins

**Bottom – Up Proteomics**



**Goal:**

- Elucidate a biomarker that indicates fiber-specific pathology *in vitro*


# PROTEOMAS workflow

## NanoInformaTIX workflow for automated data analysis

Allows for automated handling of:

- Missing meta data
- Data imputation for missing values
- Outlier detection

- First measurements are completed
- Data analysis is ongoing



# Outlook

## Comparative assessment of altered pathways:

- Regression modelling - Identify the key factors driving changes in the proteome linked to phys. chem. properties
- Analysis of observed proteomic alterations matching to publicly available data (E.g. transcriptomic data / NM proteome data / aggregated lung proteome alterations)
- Comparative analysis to Adverse Outcome Pathways (AOP) for fibrosis and frustrated phagocytosis induced cancer (**AOP 173 / 303**)
  - Substantiate existing key events / identify candidates of additional key events

# Acknowledgment



# HARMLESS



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 953183.



The BfR team: staff and technical assistants

Group 76

Special thanks to Andrea Haase, Mario Pink & Verónica Dumit



# Thank you for your attention



Identify Risks –  
Protect Health

Rico Ledwith

German Federal Institute for Risk Assessment

Max-Dohrn-Straße 8-10 • 10589 Berlin, GERMANY

Phone +49 30 - 184 12 - 0 • Fax +49 30 - 184 12 – 99 0 99

bfr@bfr.bund.de • [www.bfr.bund.de/en](http://www.bfr.bund.de/en)